

PERSONAL INFORMATION

LAURA MAZZEO


✉ laura.mazzeo@istitutotumori.mi.it; laura.mazzeo@polimi.it

POSITION

Medical Doctor, Oncologist
Bioengineering PhD Candidate

WORK EXPERIENCE

January 2023- Today

Medical Oncologist

Medical Oncology Department 1
Fondazione IRCCS Istituto Nazionale Tumori, Via Giacomo Venezian 1, 20133, Milan (MI), Italy

December 2017- December 2022

Resident Medical Doctor

Fondazione IRCCS Istituto Nazionale Tumori, Via Giacomo Venezian 1, 20133, Milan (MI), Italy
Università degli Studi di Milano, Via Festa del Perdono 7, 20122, Milan (MI), Italy

General medical doctor

September 2020- July 2022

AZIENDA SOCIO SANITARIA TERRITORIALE (ASST) DI MONZA, via Gian Battista Pergolesi, 33 - 20900 Monza
First-aid medical care
First assistance outpatient visits, medical certificates, prescription of urgent drugs

Vaccinator

June 2020- July 2021

Fondazione IRCCS Istituto Nazionale Tumori, via Venezian 1, Milano 20133 (MI)
Co.co.co.
Sars Cov2 Vaccination

General medical doctor

April 2017 – December 2017

Azienda Sanitaria Provinciale di Vibo Valentia, Via Dante Alighieri, 89900 Vibo Valentia VV
First-aid medical care
First assistance outpatient visits, medical certificates, prescription of urgent drugs

Candidate Doctor

January 2016

Dr. De Monti Marco, Department of Surgery, Ospedale Beata Vergine (OBV), EOC, Mendrisio, Swiss
Operating Theatre, Emergency room
Anamnesis, Physical examination, Differential Diagnosis, wound management, Operating theatre.

EDUCATION AND TRAINING

November 2022- Present

Doctoral (PhD) Student in Bioengineering (XXXVIII cycle)

Politecnico di Milano, Piazza Leonardo da Vinci, 32, 20133 Milano

December 2017- December 2022

Medical Oncologist Resident

Università degli Studi di Milano, Via Festa del Perdono 7, 20122, Milano (MI)

Fondazione IRCCS Istituto Nazionale Tumori, Via Giacomo Venezian 1, 20133, Milano (MI)

Directed by Dr Prof Filippo De Braud

Medical Oncology Department, Thoracic Oncology Unit

Taking Anamnesis, Physical examination, Diagnosis and Differential Diagnosis, Treatment plan, Commenting on laboratory result. Collecting data, statistical analysis, experiments, clinical examination of patients. Taking part in several translational and clinical research projects

15 February 2017–Present

Medical Doctor fully licensed

Università degli Studi di Messina, Pugliatti Square, 1, 98122, Messina (ME), Italy

Medical licence, Vote 270/270

Member of Ordine dei Medici e dei Chirurghi di Vibo Valentia, Italy

September 2010- July 2016

Degree in Medicine and Surgery

Università degli Studi di Messina, Pugliatti Square, 1, 98122, Messina (ME), Italy

Medical Training at Policlinico Universitario “G.Martino” and Ospedale Papardo, Prof. Vincenzo Adamo

Vote: 110/110 cum laude

Graduation thesis: La terapia anti HER2+ nel carcinoma mammario metastatico, dal Trastuzumab alle terapie innovative. Analisi di efficacia e nostra esperienza

August 2016

Professional Exchange Student

MUDr. Jozef Babala, PhD. Department of Paediatrics Surgery, Nemonica Kramare, DFNSP Bratislava, Slovakia

Observation in operating room

Anamnesis, Physical examination, Differential Diagnosis, wound management, Operating theatre.

September 2015

Professional Exchange Student

University of Belgrade, Serbia, Professor D. Micic, MD, PhD, Institute for Endocrinology, Diabetes and disease of metabolism

Clinical Department

Research Exchange Student

Collecting data, statistical analysis, experiments, clinical examination of patients.

PERSONAL SKILLS

Mother tongue

Italian

Other language

English

UNDERSTANDING		SPEAKING		WRITING
Listening	Reading	Spoken interaction	Spoken production	
C1	C1	C1	C1	C1

Levels: A1/A2: Basic user - B1/B2: Independent user - C1/C2 Proficient user
[Common European Framework of Reference for Languages](#)

Communication skills Excellent interpersonal skills with colleagues, even in multicultural environments; adaptation, teamwork

Organisational / managerial skills Good organisational / managerial skills.

Job-related skills I focused my education on oncology clinical care activities, to include learning about laboratory techniques and translational work. I dedicate my work to the clinical care of patients, especially lung cancer patients, thereby developing a thorough understanding of the global management of the disease.

Digital skills

SELF-ASSESSMENT				
Information processing	Communication	Content creation	Safety	Problem solving
Independent user	Independent user	Independent user	Independent user	Independent user

Levels: Basic user - Independent user - Proficient user

[Digital competences - Self-assessment grid](#)

Driving licence B

ADDITIONAL INFORMATION

Publications

Mazzeo, L., Corso, F., Baili, P., Scotti, F., Torri, V., Ganzinelli, M., Miskovic, V., Leporati, R., Provenzano, L., Spagnoletti, A., Silvestri, C., Giani, C., Cavalli, C., Mauro, R. M., Meazza Prina, M., Proto, C., Brambilla, M., Occhipinti, M., Manglaviti, S., & Prelaj, A. (2025). *Data analytics for real-world data integration in TKI-treated NSCLC patients using electronic health records*. *ESMO Real World Data and Digital Oncology*, 7, 100109. <https://doi.org/10.1016/j.esmorw.2024.100109>

Urtecho SB, Provenzano L, Spagnoletti A, Bottiglieri A, Pircher C, Massa G, Sposetti C, Proto C, Brambilla M, Occhipinti M, **Mazzeo L**, Beninato T, Leporati R, Giani C, Cavalli C, Serino R, Prina MM, Bassetti A, Nasca V, di Mauro RM, Abate A, Manglaviti S, Dumitrascu AD, Liberti GD, Cassano TS, Ganzinelli M, Wu S, Garassino MC, de Braud FGM, Russo GL, Prelaj A. Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review. *Lung Cancer*. 2025 Jan;199:108051. doi: 10.1016/j.lungcan.2024.108051. Epub 2024 Dec 9. PMID: 39740426.

Ambrosini P, Miliziano D, Liberti GD, Lorenzini D, Marchesi S, Bassetti A, Tamborini E, Leporati R, Beninato T, **Mazzeo L**, Brambilla M, Ganzinelli M, Prelaj A, Proto C, Braud FG, Russo GL, Occhipinti M. Histologic Transformation of ALK-Rearranged Lung Adenocarcinomas to High-Grade LCNEC: Clinical and Molecular Description of Three Cases. *Clin Lung Cancer*. 2025 Jan;26(1):e11-e17. doi: 10.1016/j.clc.2024.11.012. Epub 2024 Nov 25. PMID: 39665942.

Occhipinti M, Brambilla M, Di Liello R, Ambrosini P, Lobianco L, Leporati R, Salvarezza M, Vitiello F, Marchesi S, Manglaviti S, Beninato T, **Mazzeo L**, Proto C, Prelaj A, Ferrara R, Della Corte CM, Lo Russo G, de Braud F, Ganzinelli M, Viscardi G. Unleashing precision: A review of targeted approaches in pleural mesothelioma. *Crit Rev Oncol Hematol*. 2024 Nov;203:104481. doi: 10.1016/j.critrevonc.2024.104481. Epub 2024 Aug 17. Erratum in: *Crit Rev Oncol Hematol*. 2024 Sep 23:104521. doi: 10.1016/j.critrevonc.2024.104521. PMID: 39159705.

Sebri V, Marzorati C, Dorangricchia P, Monzani D, Grasso R, Prelaj A, Provenzano L, **Mazzeo L**, Dumitrascu AD, Sonnek J, Szewczyk M, Watermann I, Trovò F, Dollis N, Sarris E, Garassino MC, Bestvina CM, Pedrocchi A, Ambrosini E, Kosta S, Filip E, Soleda M, Roca AA, Rodríguez-Morató J,

Nuara A, Lourie Y, Fernandez-Pinto M, Aguaron A, Pravettoni G. The impact of decision tools during oncological consultation with lung cancer patients: A systematic review within the I3LUNG project. *Cancer Med.* 2024 May;13(9):e7159. doi: 10.1002/cam4.7159. PMID: 38741546; PMCID: PMC11091486.

Miceli R, Eriksson H, Lo Russo G, Alfieri S, Moksnes Bjaanæs M, Pietrantonio F, De Cecco L, Prelaj A, Proto C, Franzén J, McDonnell D, Berenguer Pina JJ, Beninato T, **Mazzeo L**, Giannatempo P, Verzoni E, Crown J, Helland Å, Eustace A. Gender Difference in side effects of Immunotherapy: a possible clue to optimize cancer treatment (G-DEFINER): study protocol of an observational prospective multicenter study. *Acta Oncol.* 2024 Apr 21;63:213-219. doi: 10.2340/1651-226X.2024.24179. PMID: 38647024.

Leporati R, Miliziano D, Beninato T, **Mazzeo L**, Manglaviti S, Brambilla M, Occhipinti M, Prelaj A, Proto C, Lo Russo G. Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs. *Tumori.* 2024 Apr 16;3008916241246659. doi: 10.1177/03008916241246659. Epub ahead of print. PMID: 38623748.

Cerbone L, Delfanti S, Crivellari S, De Angelis AM, **Mazzeo L**, Proto C, Occhipinti M, Lo Russo G, Dellepiane C, Biello F, Alabiso I, Verderame F, Gauna R, De Simone I, Cuppone F, Petraglia S, Pasello G, Ceresoli GL, Garassino MC, Torri V, Grosso F. Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund. *Tumori.* 2024 Jun;110(3):168-173. doi: 10.1177/03008916241229287. Epub 2024 Feb 19. PMID: 38372045.

Prelaj A, Ganzinelli M, Provenzano L, **Mazzeo L**, Viscardi G, Metro G, Galli G, Agustoni F, Corte CMD, Spagnoletti A, Giani C, Ferrara R, Proto C, Brambilla M, Dumitrascu AD, Inno A, Signorelli D, Pizzutilo EG, Brighenti M, Biello F, Bennati C, Toschi L, Russano M, Cortellini A, Catania C, Bertolini F, Berardi R, Cantini L, Pecci F, Macerelli M, Emili R, Bareggi C, Verderame F, Lugini A, Pisconti S, Buzzacchino F, Aieta M, Tartarone A, Spinelli G, Vita E, Grisanti S, Trovò F, Auletta P, Lorenzini D, Agnelli L, Sangaletti S, Mazzoni F, Calareso G, Ruggirello M, Greco GF, Vigorito R, Occhipinti M, Manglaviti S, Beninato T, Leporati R, Ambrosini P, Serino R, Silvestri C, Zito E, Pedrocchi ACL, Miskovic V, de Braud F, Prunerì G, Lo Russo G, Genova C, Vingiani A. APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research. *Clin Lung Cancer.* 2024 Mar;25(2):190-195. doi: 10.1016/j.clcc.2023.12.012. Epub 2023 Dec 22. PMID: 38262770.

Manglaviti S, Bini M, Apollonio G, Zecca E, Galli G, Sangaletti S, Labianca A, Sottotetti E, Brambilla M, Occhipinti M, Proto C, Prelaj A, Signorelli D, De Toma A, Viscardi G, Beninato T, **Mazzeo L**, Bottiglieri A, Leporati R, Fotia G, Ganzinelli M, Portararo P, Garassino MC, de Braud FGM, Lo Russo G, Torri V, Ferrara R. High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors. *Lung Cancer.* 2023 Dec;186:107417. doi: 10.1016/j.lungcan.2023.107417. Epub 2023 Oct 29. PMID: 37918061.

Prelaj A, Miskovic V, Zanitti M, Trovo F, Genova C, Viscardi G, Rebuzzi SE, **Mazzeo L**, Provenzano L, Kosta S, Favali M, Spagnoletti A, Castelo-Branco L, Dolezal J, Pearson AT, Lo Russo G, Proto C, Ganzinelli M, Giani C, Ambrosini E, Turajlic S, Au L, Koopman M, Delaloge S, Kather JN, de Braud F, Garassino MC, Pentheroudakis G, Spencer C, Pedrocchi ALG. Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review. *Ann Oncol.* 2023 Oct 23:S0923-7534(23)04331-4. doi: 10.1016/j.annonc.2023.10.125. Epub ahead of print. PMID: 37879443.

Brambilla M, Beninato T, Piemontese A, **Mazzeo L**, Pircher CC, Manglaviti S, Ambrosini P, Signorelli D, Lorenzini D, Prelaj A, Ferrara R, Proto C, Lo Russo G, Pizzutilo EG, Ganzinelli M, Grande I, Capone I, Di Mauro RM, Conca E, Dumitrascu AD, Zanella C, Leporati R, Rota S, Garassino MC, Marchetti P, de Braud FM, Occhipinti M. Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations. *Clin Lung Cancer.* 2023 Aug 23:S1525-7304(23)00149-3. doi: 10.1016/j.clcc.2023.08.004. Epub ahead of print. PMID: 37775370.

Lo Russo G, Prelaj A, Dolezal J, Beninato T, Agnelli L, Triulzi T, Fabbri A, Lorenzini D, Ferrara R, Brambilla M, Occhipinti M, **Mazzeo L**, Provenzano L, Spagnoletti A, Viscardi G, Sgambelluri F, Brich S, Miskovic V, Pedrocchi ALG, Trovo F, Manglaviti S, Giani C, Ambrosini P, Leporati R, Franza A, McCulloch J, Torelli T, Anichini A, Mortarini R, Trinchieri G, Prunerì G, Torri V, De Braud F, Proto C, Ganzinelli M, Garassino MC. PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis. *J Immunother Cancer.* 2023 Jun;11(6):e006833. doi: 10.1136/jitc-2023-006833. PMID: 37286305;

PMCID: PMC10254948.

Proto C, Manglaviti S, Lo Russo G, Musca M, Galli G, Imbimbo M, Perrino M, Cordua N, Rulli E, Ballatore Z, Maso AD, Chella A, Sbrana A, Prelaj A, Ferrara R, Occhipinti M, Brambilla M, De Toma A, **Mazzeo L**, Beninato T, Signorelli D, Massa G, Greco FG, Calareso G, Miliziano D, Di Mauro RM, Mella G, Lucarelli A, Paggio A, Galli F, Torri V, de Braud FGM, Pasello G, Petrini I, Berardi R, Ganzinelli M, Garassino MC, Zucali PA. STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines. *J Thorac Oncol.* 2023 Aug;18(8):1070-1081. doi: 10.1016/j.jtho.2023.04.009. Epub 2023 Apr 23. PMID: 37094664.

Prelaj A, Ganzinelli M, Trovo' F, Roisman LC, Pedrocchi ALG, Kosta S, Restelli M, Ambrosini E, Broggin M, Pravettoni G, Monzani D, Nuara A, Amat R, Spathas N, Willis M, Pearson A, Dolezal J, **Mazzeo L**, Sangaletti S, Correa AM, Aguaron A, Watermann I, Popa C, Raimondi G, Triulzi T, Steurer S, Lo Russo G, Linardou H, Peled N, Filip E, Reck M, Garassino MC. The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy. *Clin Lung Cancer.* 2023 Feb 28:S1525-7304(23)00039-6. doi: 10.1016/j.clcc.2023.02.005. Epub ahead of print. PMID: 36959048.

Prelaj A, Galli EG, Miskovic V, Pesenti M, Viscardi G, Pedica B, **Mazzeo L**, Bottiglieri A, Provenzano L, Spagnoletti A, Marinacci R, De Toma A, Proto C, Ferrara R, Brambilla M, Occhipinti M, Manglaviti S, Galli G, Signorelli D, Giani C, Beninato T, Pircher CC, Rametta A, Kosta S, Zanitti M, Di Mauro MR, Rinaldi A, Di Gregorio S, Antonia M, Garassino MC, de Braud FGM, Restelli M, Lo Russo G, Ganzinelli M, Trovò F and Pedrocchi ALG. *Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients.* 23/01/2023. *Front. Oncol.* 12:1078822. doi: 10.3389/fonc.2022.1078822

Zattarin E, Nichetti F, Ligorio F, **Mazzeo L**, Lobefaro R, Fucà G, Peverelli G, Vingiani A, Bianchi GV, Capri G, De Braud F, Vernieri C. Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with Advanced Extramammary Paget Disease of the groin. *Journal: Frontiers in Oncology, section Skin Cancer.* July 2022.

Fucà G, Lecchi M, Ciniselli CM, Ottini A, Spagnoletti A, **Mazzeo L**, Morelli D, Frati P, Stroschia M, Ebrahim E, Sottotetti E, Galli G, D'Elia MG, Lobefaro R, Ducceschi M, Di Guardo L, Bhoori S, Provenzano S, Platania M, Niger M, Colombo E, Nichetti F, Duca M, Rivoltini L, Mortarini R, Baili P, Apolone G, de Braud F, Verderio P, Damian S. Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center. *Ther Adv Med Oncol.* 2022 Jul 27;14:17588359221108687. doi: 10.1177/17588359221108687.

Zattarin E, Manglaviti S, Apollonio G, Beninato T, **Mazzeo L**, Massa G, Bottiglieri A, Galli E, De Toma A, Occhipinti M, Brambilla M, Ferrara R, Ganzinelli M, Proto C, Garassino MC, de Braud F, Lo Russo G, Prelaj A. Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy. *Future Oncol.* 2022 Jul;18(23):2593-2604. doi: 10.2217/fon-2021-1454. Epub 2022 Jun 20. PMID: 35722877.

Platini F, Cavalieri S, Alfieri S, Bergamini C, Resteghini C, Bottiglieri A, Colombo E, **Mazzeo L**, Licitra L, Paolini B, Seregini E, Locati LD. Late toxicities burden in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib. *Endocrine.* 2021 Sep;73(3):641-647. doi: 10.1007/s12020-021-02702-4. Epub 2021 Apr 2. PMID: 33797698.

Fucà G, Beninato T, Bini M, **Mazzeo L**, Di Guardo L, Cimminiello C, Randon G, Apollonio1 G, Bisogno I, Del Vecchio M, Lauria Pantano C, Di Nicola M, De Braud F, Del Vecchio M. *The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy.* *Targeted Oncology.* 2021 Jun <https://doi.org/10.1007/s11523-021-00819-0>

Lobefaro R, Zattarin E, Nichetti F, Prisciandaro M, Ligorio F, Brambilla M, Sepe P, Corti F, Peverelli G, Ottini A, Beninato T, **Mazzeo L**, Rea CG, Mariani G, De Braud F, Bianchi GV, Vernieri C, Capri G. *Antitumor activity and efficacy of shorter versus longer duration of anthracyclinetaxane neoadjuvant chemotherapy in stage II–III HER2-negative breast cancer: a 10-year, retrospective analysis.* *Ther Adv Med Oncol* 2020, Vol. 12: 1–13. DOI: 10.1177/ 1758835920970081

Abstract **Mazzeo L.**, Corso F., Peppoloni V., Leone G., Bisotti C., Wolf F., Miskovic V., Wiest I., Silvestri C., Occhipinti M., Brambilla M., Beninato T., Meazza Prina M., Proto C., Baili P., Ganzinelli M., Pedrocchi A., Lo Russo G., Kather J.N.N., Prelaj A. *Privacy-preserving LLMs for automated clinical feature extraction: A real-world study in NSCLC EGFR-mutated patients. JTO, 2025*

Editorial projects Advanced NSCLC: ruolo di pembrolizumab nella pratica clinica quotidiana. Caso clinico: Immunoterapia e infezione da HIV: efficacia e sicurezza del trattamento con pembrolizumab. Supplemento n. 1 a Impact Factor News n. 2 - anno 2023. Forum Service Editore.

Grants 2025 BANDO DI RICERCA ISTITUZIONALE-Istituto Nazionale Tumori di Milano.
Progetto: Extraction of immunotherapy clinical features in Non-Small Cell Lung Cancer using privacy-preserving Large Language Models.

2025 Merit Travel Grant. European Lung Cancer Congress (ELCC) 2025. Paris

2023 Scholarship for a One-Year Internship at a GIOT (Interdisciplinary Thoracic Oncology Group). FONICAP – LILT

- Congress**
- GOIRC Annual Meeting 2025, Bologna. Speaker
 - European Lung Cancer Congress (ELCC) 26-29/03/2025. Paris, France. Poster Presenter, Merit Travel Grant Recipient
 - XXVI Congresso nazionale AIOM. Roma, 08-10/11/2024
 - T&TO... Today and Tomorrow in Oncology, 4° edizione, Torino. 09/10/2024. Speaker
 - Congresso ESMO 2024, Barcelona, Spain. 13-17/09/2024
 - Artificial Intelligence for Oncology– Milan, 10/05/2024. Chair.
 - IVth edition Lung Cancer- Cocktail with science – Milan, 25/09/2023. Chair.
 - Artificial Intelligence for Oncology- background on AI methodologies and their use in the clinical practice – Milan, 05/05/2023. Chair.
 - 2nd Annual Meeting- Integrative science, Intelligent data platform for individualized LUNG cancer care with Immunotherapy (I3LUNG Project) - Barcelona, Spagna, 30 Giugno- 1 Luglio 2023- Speaker
 - Digital for Clinical Day 2022- Milan, 22/11/2022
 - 3rd edition Lung Cancer- Cocktail with science – Milan, 20/10/2022.
 - 1° Congresso nazionale Fonicap/IAIC-NET- LILT, Pacengo di Lazise (VR), 13-15/10/2022
 - XXIV Congresso nazionale AIOM. Roma, 01-02-03 ottobre 2022
 - Best of WCLC 2022- 05-07/09/2022, FAD.
 - Congresso AIOM Giovani, Multidisciplinarietà e nuove sfide" - Perugia, 8-9 luglio 2022
 - 07/04/2022 -14/07/2022 O.P.E.R.A. LUNG - Percorso formativo di approfondimento in oncologia polmonare.
 - Corso residenziale "LUNG IN YOUNG" Baveno (VB), 5-6 maggio 2022
 - SEM Profilazione molecolare e NSCLC: uno sguardo al futuro. Milano, 13/04/2022
 - XXIII Congresso nazionale AIOM. 22-23-24 ottobre 2021.
 - Cocktail with science – 14 Settembre- 11 Novembre 2021.
 - XXI Congresso nazionale AIOM. Roma, 25-26-27 ottobre 2019.
 - 4th ESO-ESMO-RCE Clinical update on rare adult solid cancers. Milano, 29/11/2019- 01/12/2019.
 - Campus in cardio/oncologia 04-05/10/2019, Artimino

- Congresso AIOM Giovani - Perugia, 5-6 luglio 2019

ESMO-The Christie Preceptorship on Lung Cancer, 1-3 March 2023, Manchester.
Multidisciplinary management, standards of care and future perspectives

Preceptorship

Good Clinical Practice training certificate, 06/2025

English Certification- TOEIC- Total Score 845, EAS Milan, 22/10/2022

Certificates

Membership

American Society of Clinical Oncology (ASCO)
European Society for Medical Oncology (ESMO)
Associazione Italiana di Oncologia Medica (AIOM)
Forza Operativa Nazionale Interdisciplinare contro il Carcinoma Polmonare (FONICAP)
European Organisation for Research and Treatment of Cancer (EORTC)
AI-ON-LAB (Artificial Intelligence in Oncology- Laboratory)- Led by Prelaj Arsela

ANNEXES

- None

"In compliance with the Italian legislative Decree no. 196 dated 30/06/2003, I hereby authorize you to use and process my personal details contained in this document."

14 May 2025

